The Valley Hospital has announced the availability of a novel procedure known as renal denervation (RDN) for certain patients suffering from high blood pressure (hypertension). The new offering comes following the approval by the U.S. Food and Drug Administration of the Symplicity Spyral Renal Denervation System manufactured by Medtronic – also known as the Medtronic Symplicity™ blood pressure procedure.
Valley is one of only three institutions in New Jersey to implement a commercial RDN program, according to Medtronic.
RDN is a minimally invasive procedure to treat resistant hypertension, defined as high blood pressure that does not respond well to multiple medications. The procedure targets nerves near the kidneys, which can become overactive and contribute to high blood pressure. According to Medtronic, this advanced technique has been used on over 25,000 patients globally, supported by an extensive body of clinical evidence surrounding the procedure.
“Renal denervation represents a major advancement in our ability to treat hypertension, especially for patients who have not seen success with traditional medications, including medications and lifestyles changes,” said Rajiv Tayal, MD, Director of the Cardiac Catheterization Laboratory and Structural Heart Program at The Valley Hospital. “Our structural heart team is excited to offer this innovative treatment to our patients, which has the potential to significantly improve their health and quality of life.”
According to the World Health Organization, high blood pressure affects over 1 billion people worldwide, and many people don’t know they have it since symptoms are often hidden.
By offering RDN, Valley aims to enhance the quality of life for patients struggling with hypertension and reduce the risks associated with uncontrolled high blood pressure, such as heart attack, stroke, and kidney damage.
To access more business news, visit NJB News Now.
Related Articles: